Latest & greatest articles for warfarin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on warfarin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on warfarin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for warfarin

1. Warfarin and other anticoagulants: monitoring of patients during the COVID-19 pandemic

Warfarin and other anticoagulants: monitoring of patients during the COVID-19 pandemic Warfarin and other anticoagulants: monitoring of patients during the COVID-19 pandemic - GOV.UK Tell us whether you accept cookies We use about how you use GOV.UK. We use this information to make the website work as well as possible and improve government services. Accept all cookies You’ve accepted all cookies. You can at any time. Hide Show or hide search Search on GOV.UK Search National restrictions (...) in England from 5 November Take action now for new rules in 2021 Warfarin and other anticoagulants: monitoring of patients during the COVID-19 pandemic Guidance has been published on monitoring of patients on warfarin and other anticoagulants during the COVID-19 pandemic. Published 22 October 2020 From: Therapeutic area: Following concerns raised by clinicians during the coronavirus (COVID-19) pandemic, we have issued regarding the safe use of warfarin and other anticoagulants. This advice has been

2020 MHRA Drug Safety Update

2. Recommendations for Clinical Warfarin Genotyping Allele Selection: A Report of the Association for Molecular Pathology and College of American Pathologists

2 variant alleles in routine clinical PGx genotyping panels. Drug: Warfarin Warfarin (brand names of Coumadin, Jantoven, and others), a coumarin anticoagulant, is one of the most widely pre- scribed drugs 6 and is administrated orally as a racemic mixture of S-warfarin and R-warfarin. The effects of warfarin and other coumarin anticoagulants are derived from inhibiting the activation of the vitamin Kedependent clotting factors. Warfarin speci?cally inhibits vitamin K epoxide reductase, an enzyme (...) Recommendations for Clinical Warfarin Genotyping Allele Selection: A Report of the Association for Molecular Pathology and College of American Pathologists SPECIAL ARTICLE Recommendations for Clinical Warfarin Genotyping Allele Selection A Report of the Association for Molecular Pathology and the College of American Pathologists Victoria M. Pratt,* y Larisa H. Cavallari,* z Andria L. Del Tredici,* x Houda Hachad,* { Yuan Ji,* k Lisa V. Kalman,** Reynold C. Ly,* yy Ann M. Moyer,* zz Stuart

2020 Association for Molecular Pathology

3. Recurrent venous thromboembolism during anticoagulation with edoxaban or warfarin: A post hoc analysis of the Hokusai-VTE trial

Recurrent venous thromboembolism during anticoagulation with edoxaban or warfarin: A post hoc analysis of the Hokusai-VTE trial Recurrent venous thromboembolism during anticoagulation with edoxaban or warfarin: A post hoc analysis of the Hokusai-VTE trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging (...) . Recurrent venous thromboembolism during anticoagulation with edoxaban or warfarin: A post hoc analysis of the Hokusai-VTE trial , , , , Affiliations Expand Affiliations 1 Dept. of Medicine I, Medical University of Vienna, Austria. Electronic address: sabine.eichinger@meduniwien.ac.at. 2 Daiichi-Sankyo Pharma Development, Basking Ridge, NJ, United States of America. 3 Dept. of Medicine I, Medical University of Vienna, Austria. PMID: 32750571 DOI: Item in Clipboard Recurrent venous thromboembolism during

2020 EvidenceUpdates

4. Risk of Bleeding with Exposure to Warfarin and Nonsteroidal Anti-Inflammatory Drugs: A Systematic Review and Meta-Analysis

Risk of Bleeding with Exposure to Warfarin and Nonsteroidal Anti-Inflammatory Drugs: A Systematic Review and Meta-Analysis Risk of Bleeding with Exposure to Warfarin and Nonsteroidal Anti-Inflammatory Drugs: A Systematic Review and Meta-Analysis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health National (...) of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Thromb Haemost Actions . 2020 Jul;120(7):1066-1074. doi: 10.1055/s-0040-1710592. Epub 2020 May 26. Risk of Bleeding with Exposure to Warfarin and Nonsteroidal Anti-Inflammatory Drugs: A Systematic Review and Meta-Analysis , , , , , , , , Affiliations Expand Affiliations 1 Skaggs School of Pharmacy and Pharmaceutical Sciences, Center for Pharmaceutical Outcomes Research, University of Colorado, Denver

2020 EvidenceUpdates

5. Association Between Use of Warfarin for Atrial Fibrillation and Outcomes Among Patients With End-Stage Renal Disease: A Systematic Review and Meta-analysis Full Text available with Trip Pro

Association Between Use of Warfarin for Atrial Fibrillation and Outcomes Among Patients With End-Stage Renal Disease: A Systematic Review and Meta-analysis Association Between Use of Warfarin for Atrial Fibrillation and Outcomes Among Patients With End-Stage Renal Disease: A Systematic Review and Meta-analysis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features (...) Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation JAMA Netw Open Actions . 2020 Apr 1;3(4):e202175. doi: 10.1001/jamanetworkopen.2020.2175. Association Between Use of Warfarin for Atrial Fibrillation and Outcomes Among Patients With End-Stage Renal Disease: A Systematic Review and Meta-analysis , , , , , , Affiliations Expand Affiliations 1 Division of Cardiology, Michigan State University

2020 EvidenceUpdates

6. Meta-Analysis Comparing Direct Oral Anticoagulants Versus Warfarin in Morbidly Obese Patients With Atrial Fibrillation

Meta-Analysis Comparing Direct Oral Anticoagulants Versus Warfarin in Morbidly Obese Patients With Atrial Fibrillation Meta-Analysis Comparing Direct Oral Anticoagulants Versus Warfarin in Morbidly Obese Patients With Atrial Fibrillation - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health National Library (...) displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Am J Cardiol Actions . 2020 Jul 1;126:23-28. doi: 10.1016/j.amjcard.2020.03.048. Epub 2020 Apr 8. Meta-Analysis Comparing Direct Oral Anticoagulants Versus Warfarin in Morbidly Obese Patients With Atrial Fibrillation , , , Affiliations Expand Affiliations 1 Department of Clinical Pharmacy, West Virginia University School of Pharmacy, Morgantown, West Virginia. Electronic address: kazuhiko.kido0322@gmail.com. 2

2020 EvidenceUpdates

7. Association Between Treatment With Apixaban, Dabigatran, Rivaroxaban, or Warfarin and Risk for Osteoporotic Fractures Among Patients With Atrial Fibrillation. (Abstract)

Association Between Treatment With Apixaban, Dabigatran, Rivaroxaban, or Warfarin and Risk for Osteoporotic Fractures Among Patients With Atrial Fibrillation. It is unclear whether anticoagulant type is associated with the risk for osteoporotic fracture, a deleterious complication of anticoagulants among patients with atrial fibrillation (AF).To compare the risk for osteoporotic fracture between anticoagulants.Population-based cohort study.Territory-wide electronic health record database (...) of the Hong Kong Hospital Authority.Patients newly diagnosed with AF between 2010 and 2017 who received a new prescription for warfarin or a direct oral anticoagulant (DOAC) (apixaban, dabigatran, or rivaroxaban). Follow-up ended on 31 December 2018.Osteoporotic hip and vertebral fractures in anticoagulant users were compared using propensity score-weighted cumulative incidence differences (CIDs).There were 23 515 patients identified (3241 apixaban users, 6867 dabigatran users, 3866 rivaroxaban users

2020 Annals of Internal Medicine

8. The Effect of Warfarin Administration Time on Anticoagulation Stability (INRange): A Pragmatic Randomized Controlled Trial Full Text available with Trip Pro

of the difference in medians) was 4.4% ( P = .62; 95% CI for the difference, -17.6% to 27.3%). Conclusions: Administration time has no statistically significant nor clinically important impact on the stability of warfarin's anticoagulant effect. Patients should take warfarin whenever regular compliance would be easiest. Keywords: Coumadin; TTR; anticoagulation; atrial fibrillation; chronotherapy; mechanical valve; practice-based research; primary care; thromboembolism; warfarin. © 2020 Annals of Family Medicine (...) The Effect of Warfarin Administration Time on Anticoagulation Stability (INRange): A Pragmatic Randomized Controlled Trial The Effect of Warfarin Administration Time on Anticoagulation Stability (INRange): A Pragmatic Randomized Controlled Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health National

2020 EvidenceUpdates

9. Equivalent inpatient mortality among direct-acting oral anticoagulant and warfarin users presenting with major hemorrhage Full Text available with Trip Pro

Equivalent inpatient mortality among direct-acting oral anticoagulant and warfarin users presenting with major hemorrhage Extrapolation of clinical trial results comparing warfarin and direct-acting oral anticoagulant (DOAC) users experiencing major hemorrhage to clinical care is challenging due to differences seen among non-randomized oral anticoagulant users, bleed location, and etiology. We hypothesized that inpatient all-cause-mortality among patients presenting with major hemorrhage (...) -mortality for 1266 propensity-score-matched patients compared using proportional hazards regression did not differ (HR = 0.84, 95%CI 0.58-1.22, p = 0.36). Inpatient all-cause-mortality in stratified analyses (warfarin as reference) produced: HR = 0.69 (95%CI 0.31-1.55) for traumatic head injuries; HR = 1.10 (95%CI 0.62-1.95) for non-traumatic head injuries; HR = 0.62 (95%CI 0.20-1.94) for traumatic, non-head injuries; and HR = 0.69 (95%CI 0.29-1.63) for non-traumatic, non-head injuries. Mean time

2020 EvidenceUpdates

10. Comparison of the Effect of Age (< 75 Versus >/= 75) on the Efficacy and Safety of Dual Therapy (Dabigatran+Clopidogrel or Ticagrelor) Versus Triple Therapy (Warfarin+Aspirin+Clopidogrel or Ticagrelor) in Patients With Atrial Fibrillation After Percutaneo Full Text available with Trip Pro

Comparison of the Effect of Age (< 75 Versus >/= 75) on the Efficacy and Safety of Dual Therapy (Dabigatran+Clopidogrel or Ticagrelor) Versus Triple Therapy (Warfarin+Aspirin+Clopidogrel or Ticagrelor) in Patients With Atrial Fibrillation After Percutaneo Comparison of the Effect of Age ( - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard, Search History (...) Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark. 10 Uppsala Clinical Research Center and Department of Medical Sciences, Uppsala University, Uppsala, Sweden. PMID: 31924322 DOI: Item in Clipboard Full-text links Cite Abstract The RE-DUAL PCI trial reported that dabigatran dual therapy (110/150 mg twice daily, plus clopidogrel or ticagrelor) reduced bleeding events versus warfarin triple therapy (warfarin plus aspirin and clopidogrel or ticagrelor) in patients with atrial

2020 EvidenceUpdates

11. Effect of Low-Intensity vs Standard-Intensity Warfarin Prophylaxis on Venous Thromboembolism or Death Among Patients Undergoing Hip or Knee Arthroplasty: A Randomized Clinical Trial. Full Text available with Trip Pro

Effect of Low-Intensity vs Standard-Intensity Warfarin Prophylaxis on Venous Thromboembolism or Death Among Patients Undergoing Hip or Knee Arthroplasty: A Randomized Clinical Trial. The optimal international normalized ratio (INR) to prevent venous thromboembolism (VTE) in warfarin-treated patients with recent arthroplasty is unknown.To determine the safety and efficacy of a target INR of 1.8 vs 2.5 for VTE prophylaxis after orthopedic surgery.The randomized Genetic Informatics Trial (GIFT (...) ) of Warfarin to Prevent Deep Vein Thrombosis enrolled 1650 patients aged 65 years or older initiating warfarin for elective hip or knee arthroplasty at 6 US medical centers. Enrollment began in April 2011 and follow-up concluded in October 2016.In a 2 × 2 factorial design, participants were randomized to a target INR of 1.8 (n = 823) or 2.5 (n = 827) and to either genotype-guided or clinically guided warfarin dosing. For the first 11 days of therapy, open-label warfarin dosing was guided by a web

2019 JAMA Controlled trial quality: predicted high

12. Atrial fibrillation: apixaban (Eliquis) as an alternative to warfarin (Coumadin and other brands) in some situations

Atrial fibrillation: apixaban (Eliquis) as an alternative to warfarin (Coumadin and other brands) in some situations Prescrire IN ENGLISH - Spotlight ''Atrial fibrillation: apixaban (Eliquis°) as an alternative to warfarin (Coumadin° and other brands) in some situations'', 1 June 2019 {1} {1} {1} | | > > > Atrial fibrillation: apixaban (Eliquis°) as an alternative to warfarin (Coumadin° and other brands) in some situations Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most (...) recent :  |   |   |   |   |   |   |   |   |  Spotlight Atrial fibrillation: apixaban (Eliquis°) as an alternative to warfarin (Coumadin° and other brands) in some situations When atrial fibrillation warrants the use of an anticoagulant, the anti-vitamin K warfarin (Coumadin° and other brands) is still the best long-term evaluated oral anticoagulant. The anti-Xa apixaban (Eliquis°) is an alternative in some situations. In patients

2019 Prescrire

13. Safety and Efficacy of Minimally Interrupted Dabigatran vs Uninterrupted Warfarin Therapy in Adults Undergoing Atrial Fibrillation Catheter Ablation: A Randomized Clinical Trial Full Text available with Trip Pro

Safety and Efficacy of Minimally Interrupted Dabigatran vs Uninterrupted Warfarin Therapy in Adults Undergoing Atrial Fibrillation Catheter Ablation: A Randomized Clinical Trial Uninterrupted dabigatran therapy reduces stroke risk in patients with nonvalvular atrial fibrillation (NVAF) undergoing ablation and is associated with a lower bleeding risk than uninterrupted warfarin therapy. Minimally interrupted direct oral anticoagulant therapy is widely used, but data from controlled studies (...) are insufficient.To compare the safety and efficacy of minimally interrupted dabigatran vs uninterrupted warfarin therapy in patients undergoing catheter ablation for NVAF.The ABRIDGE-J (ABlation peRIoperative DabiGatran in use Envisioning in Japan) trial is a open-label, randomized clinical trial performed in 28 Japanese treatment centers. A total of 504 patients scheduled for NVAF ablation were enrolled; 500 were randomized to the study treatments; 499 received at least 1 dose of dabigatran etexilate (n = 248

2019 EvidenceUpdates

14. Blood & Clots Series: How do you stop warfarin for surgery?

Blood & Clots Series: How do you stop warfarin for surgery? Blood & Clots Series: How do you stop warfarin for surgery? - CanadiEM Blood & Clots Series: How do you stop warfarin for surgery? In , by Kerstin de Wit March 19, 2019 All the content from the Blood & Clots series can be found . CanMEDS Roles addressed: Medical Expert, Scholar Case Description You are assessing a 76 year old lady who takes warfarin for stroke prevention because she had a mechanical aortic valve replacement 4 years ago (...) . She was at the preoperative clinic this morning because she will have a knee replacement surgery in a weeks time. The anesthesiologist said they would like to perform a spinal block for the surgery, and the surgeon says the patient must come off her warfarin before he can operate. She tells you she is worried about having a stroke if she stops her warfarin. You are wondering how to advise her. Can you stop the warfarin for a week before her surgery? Do you need to prescribe ‘bridging

2019 CandiEM

15. Effectiveness and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and heart failure. Full Text available with Trip Pro

Effectiveness and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and heart failure. Heart failure (HF) is a common co-morbidity in non-valvular atrial fibrillation (NVAF) patients and a potent risk factor for stroke, bleeding, and a decreased time-in-therapeutic range with warfarin. We assessed the real-world effectiveness and safety of rivaroxaban and warfarin in NVAF patients with co-morbid HF.Using US Truven MarketScan Commercial and Medicare (...) supplemental database claims data from 11/2011 to 12/2016, we identified oral anticoagulant (OAC)-naïve NVAF patients with HF (International Classification of Diseases, 10th Revision codes of I50 or I09.81) and ≥12 months of insurance coverage prior to the qualifying OAC dispensing. Rivaroxaban users (20 or 15 mg once daily) were 1:1 propensity score matched to warfarin users, with residual absolute standardized differences <0.1 being achieved for all covariates after matching. Patients were followed up

2019 ESC heart failure

16. Genotype-Guided Warfarin Dosing in Patients With Mechanical Valves: A Randomized Controlled Trial Full Text available with Trip Pro

Genotype-Guided Warfarin Dosing in Patients With Mechanical Valves: A Randomized Controlled Trial The clinical utility of genotype-guided warfarin dosing remains controversial. The objective of this trial was to evaluate the efficacy and safety of genotype-guided warfarin dosing in East Asians.A double-blind, randomized control trial was performed to compare a genotype-guided dosing algorithm (CYP2C9, VKORC1, and CYP4F2) with a clinical-guided one in the initiation treatment for patients (...) days, p = 0.009). The TTRs were 47.257% and 47.461% in the control and study group (p = 0.941), respectively. Patients with the CYP2C9 *1/*3 genotype had higher international normalized ratio (INR) variability than patients with the CYP2C9 *1/*1 genotype (p = 0.024). Compared with normal and sensitive responders, the highly sensitive responders were at increased risk of an INR of 4.0 or greater (p < 0.05).The genotype-guided warfarin dosing was safe and might be more efficient for the time to reach

2018 EvidenceUpdates

17. Association of Genetic Variants With Warfarin-Associated Bleeding Among Patients of African Descent. Full Text available with Trip Pro

Association of Genetic Variants With Warfarin-Associated Bleeding Among Patients of African Descent. Major warfarin-related bleeding occurs more frequently in African Americans than in other populations. Identification of potential genetic factors related to this adverse event may help identify at-risk patients.To identify genetic factors associated with warfarin-related bleeding in patients of African descent at an international normalized ratio (INR) of less than 4.A case-control genome-wide (...) association study involving patients of African descent taking warfarin was conducted in a discovery cohort (University of Chicago [2009-2011] and the University of Illinois at Chicago [2002-2011]), and associations were confirmed in a replication cohort (University of Chicago [2015-2016]). Potential population stratification was examined in the discovery cohort by principal component analysis. Odds ratios (ORs) and 95% CIs were computed for bleeding risk by logistic regression analysis. Summary

2018 JAMA

18. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome Full Text available with Trip Pro

Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome Rivaroxaban is an effective and safe alternative to warfarin in patients with atrial fibrillation and venous thromboembolism. We tested the efficacy and safety of rivaroxaban compared with warfarin in high-risk patients with thrombotic antiphospholipid syndrome. This is a randomized open-label multicenter noninferiority study with blinded end point adjudication. Rivaroxaban, 20 mg once daily (15 mg once daily based (...) on kidney function) was compared with warfarin (international normalized ratio target 2.5) for the prevention of thromboembolic events, major bleeding, and vascular death in patients with antiphospholipid syndrome. Only high-risk patients triple positive for lupus anticoagulant, anti-cardiolipin, and anti-β2-glycoprotein I antibodies of the same isotype (triple positivity) were included in the study. The trial was terminated prematurely after the enrollment of 120 patients (59 randomized to rivaroxaban

2018 EvidenceUpdates

19. Less abnormal uterine bleeding with dabigatran than warfarin in women treated for acute venous thromboembolism Full Text available with Trip Pro

Less abnormal uterine bleeding with dabigatran than warfarin in women treated for acute venous thromboembolism Essentials Factor Xa inhibitors cause more abnormal menstrual bleeding (AUB) than vitamin-K antagonists (VKA). We analyzed data of AUB in women, evaluating dabigatran versus VKA. We observed a 41% lower risk of AUB in women on dabigatran compared to those on VKA. Our findings of lower AUB risk on dabigatran should be corroborated in future studies.Introduction Although direct oral (...) anticoagulants (DOACs) are associated with a better safety profile than warfarin in patients with acute venous thromboembolism (VTE), direct factor Xa inhibitors involve a higher risk of abnormal uterine bleeding (AUB). We aimed to determine the risk of AUB during anticoagulation with dabigatran compared with warfarin. Methods Post-hoc analysis of the pooled RE-COVER studies and the RE-MEDY trial. Incidences of AUB, based on a defined preferred terms search for adverse events, in female patients aged 18-50

2018 EvidenceUpdates

20. Warfarin

Warfarin Top results for warfarin - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4 (...) ) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for warfarin The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted

2018 Trip Latest and Greatest